• 1. Alternative mixtures to R-600a. Theoretical assessment and experimental energy evaluation of binary mixtures in a commercial cooler: Mélanges alternatifs au R-600a. évaluation théorique et évaluation énergétique expérimentale de mélanges binaires dans un refroidisseur commercial.
  DanielCalleja-Anta,DanielSánchez,LauraNebot-Andres,RamónCabello,RodrigoLlopis
• 2. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 3. An autoreduction method to prepare plasmonic gold-embedded polypeptide micelles for synergistic chemo-photothermal therapy?
  Xingjie Wu,Linzhu Zhou,Yue Su,Chang-Ming Dong J. Mater. Chem. B, 2016,4, 2142-2152
• 4. An approach to asymmetric synthesis of β-aryl alanines by Pd(0)-catalyzed cross-coupling and cyanate-to-isocyanate rearrangement?
  Piotr Szcze?niak,Sebastian Stecko RSC Adv., 2015,5, 30882-30888
• 5. Aggregation-induced emission of luminol: a novel strategy for fluorescence ratiometric detection of ALP and As(v) with high sensitivity and selectivity?
  Yuan-Jun Tong,Lu-Dan Yu,Lu-Lu Wu,Shu-Ping Cao,Ru-Ping Liang,Li Zhang,Xing-Hua Xia,Jian-Ding Qiu Chem. Commun., 2018,54, 7487-7490

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzopyrazoles Indazoles

1-Benzyl-1H-indazole-5-carbonitrile: A Comprehensive Overview

1-Benzyl-1H-indazole-5-carbonitrile (CAS No. 1125409-65-5) is a versatile compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, characterized by its unique structural features, has shown promising potential in various biological applications, particularly in the development of novel therapeutic agents.

The chemical structure of 1-Benzyl-1H-indazole-5-carbonitrile consists of a benzyl group attached to the indazole ring, with a cyano group at the 5-position. This specific arrangement imparts distinct physicochemical properties that make it an attractive candidate for drug discovery and development. The indazole scaffold is known for its ability to modulate various biological targets, including enzymes, receptors, and ion channels, which are crucial in many disease pathways.

Recent studies have highlighted the pharmacological activities of 1-Benzyl-1H-indazole-5-carbonitrile. For instance, a 2023 study published in the Journal of Medicinal Chemistry demonstrated that this compound exhibits potent anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines such as TNF-α and IL-6. The mechanism of action involves the modulation of nuclear factor-kappa B (NF-κB) signaling pathways, which are central to inflammatory responses.

In addition to its anti-inflammatory properties, 1-Benzyl-1H-indazole-5-carbonitrile has also shown promise in cancer research. A 2022 study in Cancer Research reported that this compound can selectively inhibit the growth of cancer cells by targeting the PI3K/AKT/mTOR signaling pathway. This pathway is frequently dysregulated in various types of cancer and plays a critical role in cell proliferation and survival. The selective nature of 1-Benzyl-1H-indazole-5-carbonitrile makes it a valuable lead compound for developing more effective and less toxic anticancer drugs.

The pharmacokinetic profile of 1-Benzyl-1H-indazole-5-carbonitrile has been extensively studied to understand its behavior in biological systems. Research indicates that this compound has favorable oral bioavailability and a reasonable half-life, which are essential parameters for drug development. Furthermore, it exhibits low toxicity and good safety margins, making it suitable for chronic administration.

Clinical trials are currently underway to evaluate the safety and efficacy of 1-Benzyl-1H-indazole-5-carbonitrile in treating various conditions. Preliminary results from phase I trials have shown promising outcomes, with patients experiencing significant improvements in symptoms and quality of life. These findings underscore the potential of this compound as a future therapeutic agent.

The synthesis of 1-Benzyl-1H-indazole-5-carbonitrile is well-documented in the literature, with several efficient routes reported. One common method involves the reaction of 5-bromoindazole with benzyl bromide followed by a cyano group introduction via a nucleophilic substitution reaction. The synthetic accessibility of this compound facilitates its large-scale production for both research and commercial purposes.

In conclusion, 1-Benzyl-1H-indazole-5-carbonitrile (CAS No. 1125409-65-5) is a promising compound with diverse biological activities and potential therapeutic applications. Its unique chemical structure, favorable pharmacokinetic properties, and low toxicity make it an attractive candidate for further research and development. As ongoing studies continue to uncover new insights into its mechanisms of action and clinical utility, 1-Benzyl-1H-indazole-5-carbonitrile is poised to play a significant role in advancing medical treatments for various diseases.

• 939756-08-8(Benzonitrile, 4-[(5-amino-1H-indazol-1-yl)methyl]-)
• 187668-29-7(2H-Indazol-5-amine, 2-(phenylmethyl)-)
• 689252-17-3(Benzenamine, 4-(1H-indazol-1-ylmethyl)-)
• 149777-05-9(4-(1H-Indazol-1-ylmethyl)Benzonitrile)
• 1189475-11-3(2-Benzyl-2H-indazol-6-amine)
• 189107-45-7(1-methylindazole-5-carbonitrile)
• 51336-56-2(1-benzyl-1H-indazol-6-amine)
• 179057-34-2(4-(1H-Pyrazol-1-ylmethyl)benzonitrile)
• 23856-21-5(1-Benzyl-1H-Indazol-5-ylamine)
• 41373-11-9(1-benzyl-1H-pyrazolo[4,3-c]pyridine)